PAXLOVID Tablet is an antiviral medication containing Nirmatrelvir 150 mg and Ritonavir 100 mg, designed to treat mild-to-moderate COVID-19 in adults and children aged 12 years and older weighing at least 40 kg who have tested positive for the SARS-CoV-2 virus. This treatment is specifically recommended for patients at risk of progression to severe disease, as it helps reduce the virus’s ability to multiply in the body.
PAXLOVID works by inhibiting viral replication, making it essential to start the therapy within five days of symptom onset for optimal effectiveness. The tablet is taken orally, with or without food, as prescribed by a healthcare professional. It is crucial to complete the full course of therapy even if symptoms improve early, and patients should not self-medicate or adjust doses without medical guidance.
Some common side effects may include altered taste (dysgeusia), diarrhea, hypertension, muscle pain (myalgia), and vomiting. Patients should inform their doctor of their full medical history, including liver disease, HIV, pregnancy, cardiovascular conditions, or any other underlying health issues. Female patients using hormonal contraceptives should use additional effective birth control methods while on PAXLOVID, as Ritonavir may affect the efficacy of contraceptives.
With proper medical supervision, PAXLOVID Tablet provides a safe and effective antiviral option to reduce COVID-19 severity and prevent hospitalization.